Ronak Shah, MD
Critical Care Medicine · Hackensack, NJNPI 1336402049
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Getinge USA Sales, LLC at 34.2% of the total. 2025 is the largest year on record at $1,260, 7.8 times the $162 reported in 2019.
Across 48 payments — averaging $46.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Getinge USA Sales, LLC$765
- Boehringer Ingelheim$161
- Verathon Inc.$160
- GSK$157
- Genentech USA, Inc.$125
- Inquis Medical, Inc.$119
- plus $754 from 20 others
Across 92 payments — averaging $4745.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$437K
What the payments were for
- Consulting fees$1607%
- Travel & lodging$76534%
- Food & beverage$1,31659%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Getinge USA Sales, LLC | 2 | $765 |
| Boehringer Ingelheim | 4 | $161 |
| Verathon Inc. | 1 | $160 |
| GSK | 10 | $157 |
| Genentech USA, Inc. | 1 | $125 |
| Inquis Medical, Inc. | 3 | $119 |
| Ambu Inc. | 1 | $115 |
| Cumberland Pharmaceuticals, Inc. | 1 | $95 |
| Abiomed | 2 | $87 |
| Mylan Specialty L.p. | 3 | $48 |
| Mindray DS USA, Inc. | 1 | $47 |
| Incyte Corporation | 2 | $45 |
| La Jolla Pharmaceutical Company | 1 | $39 |
| Merck | 2 | $35 |
| Pfizer | 2 | $32 |
| Paratek Pharmaceuticals, Inc. | 2 | $30 |
| Boston Scientific | 1 | $23 |
| Beone Medicines USA, Inc. | 1 | $22 |
| Olympus America Inc. | 1 | $21 |
| Philips North America LLC | 1 | $20 |
| Grifols USA, LLC | 1 | $17 |
| AbbVie | 1 | $16 |
| United Therapeutics Corporation | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vasoview Hemopro 2$765
- Video Laryngoscope$160
- Esbriet$125
- OFEV$117
How this compares
$2,241 in reported general payments places this provider in the 75th percentile of 254 critical care medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other critical care medicine in Hackensack
- Eric TellerHackensack$217K
- Raghad SaidHackensack$48K
- Keith RoseHackensack$13K
- Sean McKayHackensack$5K
- Karan OmidvariHackensack$4K
- Eugene BunnellHackensack$3K
- Fariborz RezaiLivingston$2.3M
- R Phillip DellingerCamden$74K
- Neha VagadiaMarlton$31K
- Mark RamzyWest Orange$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.